Applied Molecular Transport Inc. (AMTI): Price and Financial Metrics
AMTI Price/Volume Stats
|Current price||$0.21||52-week high||$1.31|
|Prev. close||$0.19||52-week low||$0.13|
|Day high||$0.21||Avg. volume||481,238|
|50-day MA||$0.16||Dividend yield||N/A|
|200-day MA||$0.28||Market Cap||8.50M|
AMTI Stock Price Chart Interactive Chart >
Applied Molecular Transport Inc. (AMTI) Company Bio
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
AMTI Latest News Stream
|Loading, please wait...|
AMTI Latest Social Stream
View Full AMTI Social Stream
Latest AMTI News From Around the Web
Below are the latest news stories about APPLIED MOLECULAR TRANSPORT INC that investors may wish to consider to help them evaluate AMTI as an investment opportunity.
Looking at Applied Molecular Transport Inc.'s ( NASDAQ:AMTI ) insider transactions over the last year, we can see that...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined
Pre-market stock movers are a hot topic this morning and we're checking on the biggest ones investors will want to watch on Friday!
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif., September 21, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) ("AMT"), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development (R&D) expenses. Total R&D expen
AMTI Price Returns